Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease

F. Rodeghiero, G. Castaman, D. Meyer, P. M. Mannucci

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

In von Willebrand disease, the goal of treatment is to correct the two laboratory hallmarks of abnormal hemostasis, i.e. the deficiency of factor VIII (F VIII) and the prolonged bleeding time (BT). Since desmopressin (DDAVP) is able to achieve both these goals in the majority of patients, it is the treatment of choice. Some patients, however, are not responsive or become refractory to DDAVP. In these, blood products maintain an important therapeutic role, and there is a need to assess the efficacy of the recently available virus-inactivated plasma concentrates, which contain both FVIII and von Willebrand factor and carry a low risk of transmitting blood-borne viruses. Our survey of the data reported in the literature indicates that all available concentrates are similarly effective in attaining high and sustained levels of FVIII after infusion. Although they often shorten or normalize the prolonged BT, that effect is less uniform. Since concentrates appear efficacious in the majority of clinical situations that require the use of blood products, they should be preferred, because of their greater safety, to cryoprecipitate produced by blood banks, which cannot be virus inactivated.

Original languageEnglish
Pages (from-to)193-199
Number of pages7
JournalVox Sanguinis
Volume62
Issue number4
Publication statusPublished - 1992

Fingerprint

von Willebrand Diseases
Deamino Arginine Vasopressin
Bleeding Time
Viruses
Blood Banks
Hemophilia A
von Willebrand Factor
Hemostasis
Therapeutics
Safety

ASJC Scopus subject areas

  • Hematology

Cite this

Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. / Rodeghiero, F.; Castaman, G.; Meyer, D.; Mannucci, P. M.

In: Vox Sanguinis, Vol. 62, No. 4, 1992, p. 193-199.

Research output: Contribution to journalArticle

Rodeghiero, F. ; Castaman, G. ; Meyer, D. ; Mannucci, P. M. / Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. In: Vox Sanguinis. 1992 ; Vol. 62, No. 4. pp. 193-199.
@article{1dee9f688cba46b7a463e2f403f7443e,
title = "Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease",
abstract = "In von Willebrand disease, the goal of treatment is to correct the two laboratory hallmarks of abnormal hemostasis, i.e. the deficiency of factor VIII (F VIII) and the prolonged bleeding time (BT). Since desmopressin (DDAVP) is able to achieve both these goals in the majority of patients, it is the treatment of choice. Some patients, however, are not responsive or become refractory to DDAVP. In these, blood products maintain an important therapeutic role, and there is a need to assess the efficacy of the recently available virus-inactivated plasma concentrates, which contain both FVIII and von Willebrand factor and carry a low risk of transmitting blood-borne viruses. Our survey of the data reported in the literature indicates that all available concentrates are similarly effective in attaining high and sustained levels of FVIII after infusion. Although they often shorten or normalize the prolonged BT, that effect is less uniform. Since concentrates appear efficacious in the majority of clinical situations that require the use of blood products, they should be preferred, because of their greater safety, to cryoprecipitate produced by blood banks, which cannot be virus inactivated.",
author = "F. Rodeghiero and G. Castaman and D. Meyer and Mannucci, {P. M.}",
year = "1992",
language = "English",
volume = "62",
pages = "193--199",
journal = "Vox Sanguinis",
issn = "0042-9007",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease

AU - Rodeghiero, F.

AU - Castaman, G.

AU - Meyer, D.

AU - Mannucci, P. M.

PY - 1992

Y1 - 1992

N2 - In von Willebrand disease, the goal of treatment is to correct the two laboratory hallmarks of abnormal hemostasis, i.e. the deficiency of factor VIII (F VIII) and the prolonged bleeding time (BT). Since desmopressin (DDAVP) is able to achieve both these goals in the majority of patients, it is the treatment of choice. Some patients, however, are not responsive or become refractory to DDAVP. In these, blood products maintain an important therapeutic role, and there is a need to assess the efficacy of the recently available virus-inactivated plasma concentrates, which contain both FVIII and von Willebrand factor and carry a low risk of transmitting blood-borne viruses. Our survey of the data reported in the literature indicates that all available concentrates are similarly effective in attaining high and sustained levels of FVIII after infusion. Although they often shorten or normalize the prolonged BT, that effect is less uniform. Since concentrates appear efficacious in the majority of clinical situations that require the use of blood products, they should be preferred, because of their greater safety, to cryoprecipitate produced by blood banks, which cannot be virus inactivated.

AB - In von Willebrand disease, the goal of treatment is to correct the two laboratory hallmarks of abnormal hemostasis, i.e. the deficiency of factor VIII (F VIII) and the prolonged bleeding time (BT). Since desmopressin (DDAVP) is able to achieve both these goals in the majority of patients, it is the treatment of choice. Some patients, however, are not responsive or become refractory to DDAVP. In these, blood products maintain an important therapeutic role, and there is a need to assess the efficacy of the recently available virus-inactivated plasma concentrates, which contain both FVIII and von Willebrand factor and carry a low risk of transmitting blood-borne viruses. Our survey of the data reported in the literature indicates that all available concentrates are similarly effective in attaining high and sustained levels of FVIII after infusion. Although they often shorten or normalize the prolonged BT, that effect is less uniform. Since concentrates appear efficacious in the majority of clinical situations that require the use of blood products, they should be preferred, because of their greater safety, to cryoprecipitate produced by blood banks, which cannot be virus inactivated.

UR - http://www.scopus.com/inward/record.url?scp=0026591332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026591332&partnerID=8YFLogxK

M3 - Article

C2 - 1642002

AN - SCOPUS:0026591332

VL - 62

SP - 193

EP - 199

JO - Vox Sanguinis

JF - Vox Sanguinis

SN - 0042-9007

IS - 4

ER -